21.07.2011 • News

Abbott Laboratories Q2 Profit Surges 50%

Abbott Laboratories reported Wednesday a profit for the second quarter that surged 50% from last year, boosted largely by a significant tax benefit and sales growth. This was partially offset by higher operating costs, mainly for research and development.

Excluding items, ongoing earnings per share for the quarter grew 11% and topped analysts' expectations by a penny. The company also raised its ongoing earnings forecast for the full-year 2011, citing the strong performance to date.

The Abbott Park, Ill.-based drug maker reported net earnings of $1.94 billion or $1.23 per share for the second quarter, sharply higher than $1.29 billion or $0.83 per share in the prior-year quarter.

The results for the latest quarter primarily included a tax resolution benefit of $519 million or $0.33 per share, and $173 million or $0.11 per share charge related to acquisition.

 

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.